A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Phase 2 Completed
20 enrolled
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
Phase 2 Completed
19 enrolled 11 charts
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Phase 2 Completed
57 enrolled 18 charts
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
20 enrolled 12 charts
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
18 enrolled 12 charts
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
4 enrolled 12 charts
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Phase 2 Completed
5 enrolled
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
6 enrolled 12 charts
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
23 enrolled 11 charts
OAIE
Phase 2 Completed
81 enrolled
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Phase 2 Completed
81 enrolled 22 charts
ISG/OS-2
Phase 2 Completed
225 enrolled
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase 2 Completed
78 enrolled 11 charts
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Phase 2 Completed
56 enrolled 18 charts
Osteosarcoma
Phase 2 Completed
32 enrolled 11 charts
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Phase 2 Completed
131 enrolled 22 charts
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Phase 2 Completed
41 enrolled 15 charts
M6620 (VX-970) in Selected Solid Tumors
Phase 2 Completed
30 enrolled 15 charts
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Phase 2 Completed
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Phase 2 Completed
178 enrolled 16 charts
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Phase 2 Completed
22 enrolled 15 charts
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Phase 2 Completed
19 enrolled 12 charts
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 2 Completed
118 enrolled 24 charts
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Phase 2 Completed
13 enrolled 15 charts
Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
Phase 2 Completed
11 enrolled 6 charts
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
Phase 2 Completed
28 enrolled
OSII-TTP
Phase 2 Completed
44 enrolled
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Phase 2 Completed
46 enrolled 13 charts
Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
Phase 2 Completed
29 enrolled
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Phase 2 Completed
20 enrolled 10 charts
High-dose ICE With Amifostine
Phase 2 Completed
24 enrolled
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Phase 2 Completed
185 enrolled
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Phase 2 Completed
53 enrolled 6 charts
Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma
Phase 2 Completed
40 enrolled 6 charts
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase 2 Completed
22 enrolled 6 charts
OCR
Phase 2 Completed
49 enrolled 7 charts
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Phase 2 Completed
178 enrolled 6 charts
SERIO
Phase 2 Completed
38 enrolled
GEIS-29
Phase 2 Completed
33 enrolled
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Phase 2 Completed
100 enrolled
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Phase 2 Completed
49 enrolled 21 charts
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 2 Completed
116 enrolled 8 charts
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Phase 2 Completed
216 enrolled
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Phase 2 Completed
120 enrolled
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Phase 2 Completed
53 enrolled
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Phase 2 Completed
15 enrolled 7 charts
Alanosine in Treating Patients With Cancer
Phase 2 Completed
Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Phase 2 Completed
Trastuzumab in Treating Patients With Recurrent Osteosarcoma
Phase 2 Completed
Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
Phase 2 Completed